BTAI
Price:
$0.3464
Market Cap:
$17.19M
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials e...[Read more]
Industry
Biotechnology
IPO Date
2018-03-08
Stock Exchange
NASDAQ
Ticker
BTAI
According to BioXcel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.17. This represents a change of -81.52% compared to the average of -0.92 of the last 4 quarters.
The mean historical PE Ratio of BioXcel Therapeutics, Inc. over the last ten years is -47.36. The current -0.17 PE Ratio has changed -64.11% with respect to the historical average. Over the past ten years (40 quarters), BTAI's PE Ratio was at its highest in in the September 2023 quarter at -0.37. The PE Ratio was at its lowest in in the March 2017 quarter at -81.55.
Average
-47.36
Median
-7.36
Minimum
-276.46
Maximum
-0.48
Discovering the peaks and valleys of BioXcel Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 152.15%
Maximum Annual PE Ratio = -0.48
Minimum Annual Increase = -92.09%
Minimum Annual PE Ratio = -276.46
Year | PE Ratio | Change |
---|---|---|
2023 | -0.48 | -86.29% |
2022 | -3.50 | -30.36% |
2021 | -5.03 | -58.84% |
2020 | -12.22 | 65.97% |
2019 | -7.36 | 152.15% |
2018 | -2.92 | -92.09% |
2017 | -36.91 | -54.65% |
2016 | -81.40 | -70.56% |
The current PE Ratio of BioXcel Therapeutics, Inc. (BTAI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.00
5-year avg
-5.72
10-year avg
-47.36
BioXcel Therapeutics, Inc.’s PE Ratio is greater than Terns Pharmaceuticals, Inc. (-5.24), greater than Amylyx Pharmaceuticals, Inc. (-1.07), greater than Acumen Pharmaceuticals, Inc. (-1.30), greater than Inozyme Pharma, Inc. (-1.97), greater than X4 Pharmaceuticals, Inc. (-6.92), greater than Day One Biopharmaceuticals, Inc. (-14.55), greater than Mirati Therapeutics, Inc. (-11.26), greater than Apellis Pharmaceuticals, Inc. (-16.45), less than Exelixis, Inc. (20.48), greater than TG Therapeutics, Inc. (-325.88), greater than Viking Therapeutics, Inc. (-47.34), greater than Madrigal Pharmaceuticals, Inc. (-13.03), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Elevation Oncology, Inc. (-0.81), greater than Mereo BioPharma Group plc (-12.36), less than Hepion Pharmaceuticals, Inc. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-5.24 | $503.69M | |
-1.07 | $278.99M | |
-1.30 | $106.34M | |
-1.97 | $193.36M | |
-6.92 | $98.42M | |
-14.55 | $1.28B | |
-11.26 | $4.12B | |
-16.45 | $4.13B | |
20.48 | $9.56B | |
-325.88 | $5.02B | |
-47.34 | $4.72B | |
-13.03 | $6.78B | |
-0.00 | $941.00 | |
-0.81 | $33.90M | |
-12.36 | $524.55M | |
-0.15 | $3.48M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioXcel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioXcel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BioXcel Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for BioXcel Therapeutics, Inc. (BTAI)?
What is the highest PE Ratio for BioXcel Therapeutics, Inc. (BTAI)?
What is the 3-year average PE Ratio for BioXcel Therapeutics, Inc. (BTAI)?
What is the 5-year average PE Ratio for BioXcel Therapeutics, Inc. (BTAI)?
How does the current PE Ratio for BioXcel Therapeutics, Inc. (BTAI) compare to its historical average?